These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23237847)

  • 21. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
    Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
    Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.
    Nan H; Han L; Ma J; Yang C; Su R; He J
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1684-1692. PubMed ID: 29408595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
    Carpten JD; Faber AL; Horn C; Donoho GP; Briggs SL; Robbins CM; Hostetter G; Boguslawski S; Moses TY; Savage S; Uhlik M; Lin A; Du J; Qian YW; Zeckner DJ; Tucker-Kellogg G; Touchman J; Patel K; Mousses S; Bittner M; Schevitz R; Lai MH; Blanchard KL; Thomas JE
    Nature; 2007 Jul; 448(7152):439-44. PubMed ID: 17611497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.
    Rädler PD; Wehde BL; Wagner KU
    Mol Cell Endocrinol; 2017 Aug; 451():31-39. PubMed ID: 28495456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
    Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.
    Aksamitiene E; Achanta S; Kolch W; Kholodenko BN; Hoek JB; Kiyatkin A
    Cell Signal; 2011 Nov; 23(11):1794-805. PubMed ID: 21726627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
    Gao SP; Kiliti AJ; Zhang K; Vasani N; Mao N; Jordan E; Wise HC; Shrestha Bhattarai T; Hu W; Dorso M; Rodrigues JA; Kim K; Hanrahan AJ; Razavi P; Carver B; Chandarlapaty S; Reis-Filho JS; Taylor BS; Solit DB
    Mol Cancer Res; 2021 Apr; 19(4):573-584. PubMed ID: 33303690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
    Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
    Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
    Parikh C; Janakiraman V; Wu WI; Foo CK; Kljavin NM; Chaudhuri S; Stawiski E; Lee B; Lin J; Li H; Lorenzo MN; Yuan W; Guillory J; Jackson M; Rondon J; Franke Y; Bowman KK; Sagolla M; Stinson J; Wu TD; Wu J; Stokoe D; Stern HM; Brandhuber BJ; Lin K; Skelton NJ; Seshagiri S
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19368-73. PubMed ID: 23134728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatidylinositol 3-kinase-dependent activation of mammalian protein kinase B/Akt in Saccharomyces cerevisiae, an in vivo model for the functional study of Akt mutations.
    Rodríguez-Escudero I; Andrés-Pons A; Pulido R; Molina M; Cid VJ
    J Biol Chem; 2009 May; 284(20):13373-13383. PubMed ID: 19307184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.
    Ooms LM; Binge LC; Davies EM; Rahman P; Conway JR; Gurung R; Ferguson DT; Papa A; Fedele CG; Vieusseux JL; Chai RC; Koentgen F; Price JT; Tiganis T; Timpson P; McLean CA; Mitchell CA
    Cancer Cell; 2015 Aug; 28(2):155-69. PubMed ID: 26267533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis.
    Ung MH; Wang GL; Varn FS; Cheng C
    Oncotarget; 2016 Dec; 7(51):84142-84154. PubMed ID: 27589846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
    Shimoi T; Hashimoto J; Sudo K; Shimomura A; Noguchi E; Shimizu C; Yunokawa M; Yonemori K; Yoshida H; Yoshida M; Kato T; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
    BMC Cancer; 2021 Oct; 21(1):1131. PubMed ID: 34670536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.